| Alemtuzumab | | For treatment of B-cell chronic lymphocytic leukemia |
| Alitretinoin | | For topical treatment of cutaneous lesions in patients with AIDS- related Kaposi sarcomaia. |
| Altretamine | | For use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination |
| Amsacrine | | For treatment of acute myeloid leukaemia. |
| Arsenic Trioxide | | For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15; 17) translocation or PML/RAR-alpha gene expression |
| Asparaginase | | For treatment of acute lympocytic leukemia and non-Hodgkins lymphoma |
| Bevacizumab | | For treatment of metastatic colorectal cancer |
| Bexarotene | | For the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy |
| Bleomycin | | For palliative treatment in the management of the following neoplasms; Malignant neoplasm (trachea, bronchus, lung); Squamous cell carcinoma; Lymphomas |
| Busulfan | | For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. |
| Capecitabine | | For the treatment of patients with metastatic breast cancer resistant to both |
| Carboplatin | | For the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of PARAPLATIN and cyclophosphamide. |
| Carmustine | | For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas. |
| Celecoxib | | For relief and management of osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, acute pain, primary dysmenorrhea and oral adjunct to usual care for patients with familial adenomatous polyposis |
| Cetuximab | | For treatment of metastatic colorectal cancer |
| Chlorambucil | | For treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease |
| Cisplatin | | For the management of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer. |
| Cladribine | | For the treatment of active Hairy Cell Leukemia as defined by clinically |
| Cyclophosphamide | | For management of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma and carcinoma of the breast |
| Cytarabine | | For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia. |
| Dacarbazine | | For the treatment of metastatic malignant melanoma. in addition, DTIC-Dome is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents |
| Dactinomycin | | For the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen |
| Daunorubicin | | For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults |
| Denileukin diftitox | | For treatment of cutaneous T-cell lymphoma |
| Doxorubicin | | For the Treatment of Koposi's sarcome connected to AIDS |
| Epirubicin | | For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer |
| Estramustine | | For the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate |
| Etoposide | | For management of refractory testicular tumors and small cell lung carcinoma. |
| Fludarabine | | For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen |
| Fluorouracil | | For the topical treatment of multiple actinic or solar keratoses. in the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, rectum, breast, stomach and pancrease. |
| Gemcitabine | | For the first-line treatment of patients with metastatic breast cancer , locally |
| Gemtuzumab ozogamicin | | For treatment of acute myeloid leukemia |
| Hydroxyurea | | For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia |
| Idarubicin | | For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7. |
| Ifosfamide | | For third line chemotherapy of germ cell testicular cancer. It should ordinarily be used in combination with a prophylactic agent for hemorrhagic cystitis, such as mesna |
| Irinotecan | | For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin) |
| Lomustine | | For use as a single agent in addition to other treatment modalities to treat |
| Marimastat | | For the treatment of various cancers |
| Mechlorethamine | | For the palliative treatment of Hodgkinâ??s disease (Stages III and IV), |
| Melphalan | | Used to treat cancer of the ovaries and a certain type of cancer in the bone marrow |
| Methotrexate | | For the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole; Severe psoriasis; Severe, active, classical or definite rheumatoid arthritis; |
| Mitomycin | | For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive |
| Mitotane | | For treatment of inoperable adrenocortical tumours; Cushing's syndrome |
| Mitoxantrone | | For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis |
| Oxaliplatin | | For the treatment of malignant neoplasm of colon, rectum, and ovary |
| Paclitaxel | | For the treatment of breast and ovarian cancer |
| Pegaspargase | | For treatment of acute lymphoblastic leukemia |
| Pemetrexed | | For the treatment of malignant pleural mesothelioma and locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy |
| Pentostatin | | For the treatment of hairy cell leukaemia refractory to alpha interferon |
| Pipobroman | | For the treatment of polycythaemia vera and refractory chronic myeloid leukaemia. |
| Porfimer | | Indicated in the treatment of esophageal cancer. |
| Procarbazine | | For use with other anticancer drugs for the treatment of stage III and stage IV Hodgkin's disease. |
| Raltitrexed | | For the treatment of malignant neoplasm of colon and rectum |
| Rituximab | | For treatment of B-cell non-Hodgkins lymphoma (CD20 positive) |
| Streptozocin | | For the treatment of malignant neoplasms of pancreas (metastatic islet cell |
| Temozolomide | | For the treatment of adult patients diagnosed with anaplastic astrocytoma who have relapsed following chemotherapy |
| Teniposide | | Treatment of refractory acute lymphoblastic leukaemia |
| Thioguanine | | For treatment of acute nonlymphocytic leukaemia |
| Topotecan | | For the treatment of metastatic carcinoma of the ovary and small cell lung cancer following the failure of first-line chemotherapy. |
| Trastuzumab | | For treatment of HER2-positive metatsatic breast cancer |
| Tretinoin | | For the the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant); For the topical treatment of acne vulgaris, flat warts and other skin conditions (psoriasis, ichthyosis congenita, icthyosis vulgaris, lamellar icthyosis, keratosis palmaris et plantaris, epidermolytic hyperkeratosis, senile comedones, senile keratosis, keratosis follicularis (Darier's disease), and basal cell carcinomas.); For palliative therapy to improve fine wrinkling, mottled hyperpigmentation, roughness associated with photodamage. |
| Valrubicin | | Bladder cancer |
| Vinblastine | | For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma. |
| Vincristine | | For treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, acute panmyelosis |
| Vindesine | | For the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis |
| Vinorelbine | | For the treatment of non-small-cell lung carcinoma |
